Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 3, 2002, Pages 952-958

  Hansard, Matthew J ^a   Smith, Lance A ^a   Jackson, Michael J ^a   Cheetham, Sharon C ^b   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b RenaSci Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMFEBUTAMONE; BTS 74 398; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; NISOXETINE; NOMIFENSINE; NORADRENALIN; SEROTONIN; SERTRALINE; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; MALE; MARMOSET; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CALLITHRIX; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; INJECTIONS, SUBCUTANEOUS; MALE; MOTOR ACTIVITY; MOTOR SKILLS; NOREPINEPHRINE; PARKINSONIAN DISORDERS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0036894662     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.039743     Document Type: Article

References (44)

1. Bezard E, Brefel C, Tison F, Peyro-Saint-Paul H, Rascal O, and Gross CE (1999) Effect of the α2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog Neuropsychopharmacol Biol Psychiatry 23:1237-1246.
2. 3H]spiperone binding. Brain Res 379:294-299.
3. Bedard P, Parkes JD, and Marsden CD (1977) Nomifensine in Parkinson's disease. Br J Clin Pharmacol 4:187S-190S.
4. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, and Kopin IJ (1983) A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546-4550.
5. Cass WA, Zahniser NR, Flach K, and Gerhardt GA (1993) Clearance of exogenous dopamine in rat dorsal striatum and nucleus accumbens: Role of metabolism and effects of locally applied uptake inhibitors. J Neurochem 61:2269-2278.
6. Ceravolo R, Nuti A, Piccinni A, Dell'Agnello G, Bellini G, Gambaccini G, Dell'Osso L, Murri L, and Bonuccelli U (2000) Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms. Neurology 55:1216-1218.
7. Cheetham S, Butler S, Hearson M, Kerrigan F, Martin K, Needham P, Prow M, Sargent B, Slater N, Skill M, et al. (1998) BTS 74 398: A novel monoamine reuptake inhibitor for the treatment of Parkinson's disease. Br J Pharmacol 123:224P.
8. Chopin P, Colpaert FC, and Marien M (1999) Effects of α-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther 288:798-804.
9. Ehringer H and Hornykiewicz O (1960). Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen. Wien Klin Wochenschr 38:1236-1239.
10. Delwaide PJ, Martinelli P, and Schoenen J (1983) Mazindol in the treatment of Parkinson's disease. Arch Neural 40:788-790.
11. Di Rocco A, Brannan T, Prikhojan A, and Yahr MD (1998) Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism. J Neural Transm 105:247-251.
12. Durif F, Vidailhet M, Bonnet AM, Blin J, and Agid Y (1995) Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 45:1855-1858.
13. 2c receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neural 151:35-49.
14. 2c receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 36:205-221.
15. Goetz CG, Tanner CM, and Klawans HL (1984) Bupropion in Parkinson's disease. Neurology 34:1092-1094.
16. Grondin R, Hadj Tahar A, Doan VD, Ladure P, and Bedard PJ (2000) Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn-Schmiedeberg's Arch Pharmacol 361:181-186.
17. Heikkila RE and Manzino L (1984) Behavioural properties of GBR 12909, GBR 13069 and GBR 13098: Specific inhibitors of dopamine uptake. Eur J Pharmacol 103:241-248.
18. Hurtig HI (1997) Problems with current pharmacological treatment of Parkinson's disease. Exp Neural 144:10-16.
19. Jackson HC, Cheetham SC, Gosden J, Hutchins LJ, Kerrigan F, Needham AM, Pleasance IM, Sargent BJ, and Heal DJ (1998) Behavioural effects of the monoamine reuptake inhibitor, BTS 74 398, in rats and mice. Br J Pharmacol 123:256P.
20. Jenner P, Rupniak NMJ, Rose S, Kelly E, Kilpatrick G, Lees A, and Marsden CD (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 50:85-90.
21. Koe BK, Weissman A, Welch WM, and Browne RG (1983) Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 226:686-700.
22. Korsgaard S, Gerlach J, and Christensson E (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharrnacol 118:245-252.
23. Korsgaard S, Noring U, Povlsen UJ, and Gerlach J (1986) Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism. Clin Neuropharmacol 9:52-57.
24. Langston JW, Forno LS, Rebert CS, and Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 292:390-394.
25. Lieberman A, Ranhosky A, and Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study. Neurology 49:162-168.
26. Marsden CD (1990) Parkinson's disease. Lancet. 335:948-952.
27. 2 agonists and antagonists. Brain Res 562:216-224.
28. Montastruc JL, Rascol O, Senard JM, and Rascol A (1994) A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five year follow up. J Neurol Neurosurg Psychiatry 57:1034-1038.
29. Nakachi N, Kiuchi Y, Inagaki M, Inazu M, Yamazaki Y, and Oguchi K (1995) Effects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats. Eur J Pharmacol 281:195-203.
30. Nomikos GC, Damsma G, Wenkstern D, and Fibiger HC (1990) In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6:106-112.
31. Olanow CW, Fahn S, Meunter M, Klawans H, Hurtig H, Stem M, Shoulson I, Kurlan R, Grimes JD, Jankovic J, et al. (1994) A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 9:40-47.
32. Park DM, Findley LJ, and Teychenne PF (1977) Nomifensine in Parkinsonism. J Clin Pharmacol 4:185S-186S.
33. Park DM, Findley LJ, Hanks G, and Sandler M (1981) Nomifensine: Effect in Parkinsonian patients not receiving levodopa. J Neurol Neurosurg Psychiatry 44:352-354.
34. Pearce RKB, Smith LA, Jackson MJ, Banerji T, Scheel-Kruger J, and Jenner P (2002) The dopamine reuptake inhibitor brasofensine reverses akinesia without dyskinesia in MPTP-treated and L-DOPA-primed common marmosets. Mov Disord, in press.
35. Rampello L, Chiechio S, Raffaele R, Vecchio I, and Nicoletti F (2002) The SSRI, Citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-DOPA. Clin Neuropharm 25:21-24.
36. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, and Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484-1491.
37. Richelson E and Pfenning M (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104:277-286.
38. Rutter JJ, Gundlah C, and Auerbach SB (1995) Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation. Synapse. 20:225-233.
39. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, and Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275:321-328.
40. Smith LA, Gordin A, Jenner P, and Marsden CD (1997) Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord 12:935-945.
41. Smith LA, Cheetham S, Maratos E, Heal DJ, Jenner P, and Marsden CD (1998) BTS 74 398 reverses motor deficits in MPTP-treated common marmosets without inducing dyskinesias. Br J Pharmacol 123:253P.
42. Teychenne PF, Park DM, Findley LJ, Clifford Rose F, and Calne DB (1976) Nomifensine in parkinsonism. J Neurol Neurosurg Psychiatry 39:1219-1221.
43. Wong DT, Horng JS, and Bymaster FP (1975) DL-N-methyl-3-(O-methoxyphenoxy)-3-phenylpropylamine hydrochloride, Lilly 94939, a potent inhibitor for the uptake of norepinephrine into rat brain synaptosomes and heart. Life Sci 17:755-760.
44. Yamato H, Kannari K, Shen H, Suda T, and Matsunaga M (2001) Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport 12:1123-1126.